Filing Details
- Accession Number:
- 0001209191-14-062640
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-10-09 16:13:44
- Reporting Period:
- 2014-10-07
- Filing Date:
- 2014-10-09
- Accepted Time:
- 2014-10-09 16:13:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1610876 | Jeffrey Chodakewitz | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp Gmda, Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-10-07 | 3,436 | $73.51 | 12,936 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-10-07 | 902 | $103.64 | 12,034 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-10-07 | 2,134 | $104.31 | 9,900 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-10-07 | 400 | $105.36 | 9,500 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2014-10-07 | 3,436 | $0.00 | 3,436 | $73.51 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
51,564 | 2024-01-01 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $103.64 (range $103.03 to $104.01).
- Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $104.31 (range $104.03 to $104.92).
- Open market sales reported on this line occurred at a weighted average price of $105.36 (range $105.20 to $105.64).
- The option vests in 16 quarterly installments from 01/02/2014.